Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Coagulation factor V: an old star shines again

J Rosing1, G Tans

  • 1Department of Biochemistry, Maastricht University, The Netherlands. j.rosing@bioch.unimass.nl

Thrombosis and Haemostasis
|July 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resistance to activated protein C and impaired TFPI activity in women with previous hormone-induced venous thromboembolism.

Thrombosis research·2021
Same author

New functional assays to selectively quantify the activated protein C- and tissue factor pathway inhibitor-cofactor activities of protein S in plasma.

Journal of thrombosis and haemostasis : JTH·2017
Same author

The C-terminus of tissue factor pathway inhibitor-α inhibits factor V activation by protecting the Arg<sup>1545</sup> cleavage site.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Tissue factor-independent inhibition of thrombin generation by tissue factor pathway inhibitor-α.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Changes in haemostatic parameters during the menstrual cycle and subsequent use of drospirenone-containing oral contraceptives.

Thrombosis research·2014
Same author

Inhibition of tissue factor:factor VIIa-catalyzed factor IX and factor X activation by TFPI and TFPI constructs.

Journal of thrombosis and haemostasis : JTH·2014
Same journal

Discontinuation of Oral Anticoagulation After Successful Catheter Ablation for Atrial Fibrillation: Meta-analysis of Randomized Clinical Trials.

Thrombosis and haemostasis·2026
Same journal

Novel/Recurrent Variants in Pakistani Glanzmann Thrombasthenia and Glanzmann-like bleeding diathesis: Insights from NGS Analysis.

Thrombosis and haemostasis·2026
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
See all related articles

Blood coagulation factor V (FV) is crucial for thrombin generation. Its activated form, factor Va, is regulated by the protein C pathway, essential for hemostatic balance. Further research on mutated FV, like FVLeiden, enhances understanding of this regulation.

Area of Science:

  • Biochemistry
  • Hematology
  • Molecular Biology

Background:

  • Factor V (FV) is a key regulator of thrombin formation.
  • Activation of FV yields factor Va, a cofactor accelerating prothrombin activation.
  • The protein C pathway down-regulates factor Va activity, maintaining hemostatic balance.

Purpose of the Study:

  • To review the structural knowledge of FV and Va.
  • To elucidate molecular changes during FV activation.
  • To detail the function of Va in prothrombin activation and its inactivation by activated protein C (APC).

Main Methods:

  • Review of existing literature on factor V structure and function.
  • Analysis of molecular changes during factor V activation.
  • Examination of the mechanism of factor Va inactivation by APC.

Related Experiment Videos

  • Consideration of studies involving mutated factor V molecules (e.g., FVLeiden).

    • Main Results:

    • Significant progress in understanding the structure-function relationship of FV and Va.
    • FVLeiden mutation has advanced knowledge of FV Va regulation by the protein C pathway.
    • Modulation of APC activity by protein S and factor Xa impacts in vivo pathway activity.
    • FV acts as a cofactor in APC-mediated inactivation of factor VIIIa.

    Conclusions:

    • Recombinant DNA technology and studies of mutated FV molecules are vital for resolving remaining questions.
    • The protein C pathway presents an intricate mechanism for regulating thrombin formation.
    • Extensive in vivo studies are necessary to fully understand thrombin formation regulation via the protein C pathway.